Next Article in Journal
Wilson’s Disease: Facing the Challenge of Diagnosing a Rare Disease
Next Article in Special Issue
Microbiota and Myopericarditis: The New Frontier in the Car-Diological Field to Prevent or Treat Inflammatory Cardiomyo-Pathies in COVID-19 Outbreak
Previous Article in Journal
The Efficacy of Naïve versus Modified Mesenchymal Stem Cells in Improving Muscle Function in Duchenne Muscular Dystrophy: A Systematic Review
Previous Article in Special Issue
Probiotic Bifidobacterium bifidum G9-1 Has a Preventive Effect on the Acceleration of Colonic Permeability and M1 Macrophage Population in Maternally Separated Rats
Review

Microbiome First Medicine in Health and Safety

Department of Microbiology and Immunology, Cornell University, Ithaca, NY 14853, USA
Academic Editor: Amedeo Amedei
Biomedicines 2021, 9(9), 1099; https://doi.org/10.3390/biomedicines9091099
Received: 27 July 2021 / Revised: 16 August 2021 / Accepted: 23 August 2021 / Published: 27 August 2021
(This article belongs to the Special Issue Pharmacomicrobiomics in Non-communicable Disease)
Microbiome First Medicine is a suggested 21st century healthcare paradigm that prioritizes the entire human, the human superorganism, beginning with the microbiome. To date, much of medicine has protected and treated patients as if they were a single species. This has resulted in unintended damage to the microbiome and an epidemic of chronic disorders [e.g., noncommunicable diseases and conditions (NCDs)]. Along with NCDs came loss of colonization resistance, increased susceptibility to infectious diseases, and increasing multimorbidity and polypharmacy over the life course. To move toward sustainable healthcare, the human microbiome needs to be front and center. This paper presents microbiome-human physiology from the view of systems biology regulation. It also details the ongoing NCD epidemic including the role of existing drugs and other factors that damage the human microbiome. Examples are provided for two entryway NCDs, asthma and obesity, regarding their extensive network of comorbid NCDs. Finally, the challenges of ensuring safety for the microbiome are detailed. Under Microbiome-First Medicine and considering the importance of keystone bacteria and critical windows of development, changes in even a few microbiota-prioritized medical decisions could make a significant difference in health across the life course. View Full-Text
Keywords: chronic disorders; inflammation; human superorganism; holobiont; microbiome; multimorbidity; microimmunosome; polypharmacy; drug safety; sustainable healthcare chronic disorders; inflammation; human superorganism; holobiont; microbiome; multimorbidity; microimmunosome; polypharmacy; drug safety; sustainable healthcare
Show Figures

Figure 1

MDPI and ACS Style

Dietert, R.R. Microbiome First Medicine in Health and Safety. Biomedicines 2021, 9, 1099. https://doi.org/10.3390/biomedicines9091099

AMA Style

Dietert RR. Microbiome First Medicine in Health and Safety. Biomedicines. 2021; 9(9):1099. https://doi.org/10.3390/biomedicines9091099

Chicago/Turabian Style

Dietert, Rodney R. 2021. "Microbiome First Medicine in Health and Safety" Biomedicines 9, no. 9: 1099. https://doi.org/10.3390/biomedicines9091099

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop